Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHINOOK benralizumab study in severe eosinophilic asthma
2018-003391-13Phase 4Active
- Sponsor
- AstraZeneca
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in eosinophilic asthma (EA) comparing Benralizumab with Placebo (2 arms). Primary endpoint: Change in submucosal eosinophils in endobronchial biopsies. Started Jun 2019; status: active.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2018-003391-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003391-13.